Infliximab for Crohn's Disease: More Than 13 Years of Real-world Experience.

ABSTRACT:

Background

The purpose of this study was to compare the long-term safety of infliximab and nonbiologic agents as Crohn's disease (CD) therapy.

Methods

Patients with CD were prospectively evaluated in this large, observational registry.

Results

Patients (n = 6273) participated in this observational registry from July 1999 through March 2012; 3440 (54.8%) received infliximab (20,971 patient-years), and 2833 (45.2%) received other treatments only (14,806 patient-years). Overall, 59,875 infliximab infusions were administered (80%, 5 mg/kg); 3006 (89.9%) patients received ≥2 infusions. Adverse events (AEs), most commonly those related to CD (eg, abdominal pain, diarrhea), and serious AEs occurred at a higher rate among infliximab-treated patients. Mortality (0.57/100 patie

SUBMITTER: Lichtenstein GR 

PROVIDER: S-EPMC6176880 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature